Omalizumab effectively protects against early- and late allergic responses in asthma after 4 weeks

Abstract

Omalizumab is licensed for therapy in severe allergic asthma with an effect demonstrated after 8 weeks or longer treatment. Since new applications for omalizumab demand precise knowledge of the onset of effects, the objective of this study was to determine the time course of the early (EAR) and late allergic reaction (LAR). Ten patients (IgE >300 IU/mL and <700 IU/mL) with a significant response to allergen challenge were treated with omalizumab according to the approved dosing table. Bronchial allergen provocations (BAP) were repeated at week 1, 2, 4 and 8. EAR was significantly reduced after 4 weeks (ΔFEV1 28 vs. 11%; p<0.001), eNO (86 vs. 53ppb; p<0.05) and basophil activation after 2 weeks (CD63 expression 79 vs. 32%, p<0.05) and LAR already after 1 week (ΔFEV1 26 vs. 13%, p<0.05). These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy.

This article is protected by copyright. All rights reserved.

http://ift.tt/2rCcNfF